Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma

OBJECTIVE: Our study aimed to investigate the potential clinical utility of a poly(ADP‐ribose) polymerase (PARP) inhibitor, veliparib (ABT‐888), as a radiosensitizer in the medication of endometrial carcinoma (EC). METHODS: Human Ishikawa endometrial adenocarcinoma cells were treated with veliparib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Xing, Weizhen, Lin, Yanling, Uskenbayeva, Nuray, Yan, Hongchao, Xu, Yang, Fang, Lisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102625/
https://www.ncbi.nlm.nih.gov/pubmed/35421273
http://dx.doi.org/10.1002/jcla.24435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102625/
https://www.ncbi.nlm.nih.gov/pubmed/35421273
http://dx.doi.org/10.1002/jcla.24435

Ejemplares similares